Pityriasis rubra pilaris

被引:1
|
作者
Quenan, S. [1 ]
Laffitte, E. [1 ]
机构
[1] HUG, Serv Dermatol, CH-1211 Geneva, Switzerland
来源
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2018年 / 145卷 / 01期
关键词
Pityriasis ruba pilaris; Folicular corneal papule; Palmoplantar keratoderma; Retinoids; Methotrexate; Cyclosporine; Anti-TNF; Anti-IL-12/23; Erythroderma; LONG-TERM; INFLIXIMAB TREATMENT; ORAL ALITRETINOIN; ACITRETIN THERAPY; ULTRAVIOLET-B; CASE SERIES; ETANERCEPT; ADALIMUMAB; USTEKINUMAB; TYPE-1;
D O I
10.1016/j.annder.2017.11.013
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pityriasis rubra pilaris is a rare heterogeneous dermatosis associating three clinical signs to different degrees: follicular corneal papules, reddish-orange palmoplantar keratoderma and erythematosquamous lesions that may in some cases be very extensive, interspersed with patches of healthy skin. The aetiology is unclear, and in most cases, the trigger factors consist of trauma or infection, probably in subjects with an existing predisposition. In other cases, the condition is associated with immunological disorders or, in familial cases, genetic keratinisation abnormalities similar to ichthyosis. Given the widely varying signs, several classifications have been proposed, based on clinical criteria and outcomes. The outcome varies in accordance with the clinical forms involved. Therapeutic approaches are poorly qualified and there have been no clinical trials due to the rarity of the disease. However, the best results appear to have been obtained using oral retinoids, with second-line therapy comprising methotrexate and cyclosporine. The landscape of therapeutic strategy seems to be changing with the advent of new anti-tumour necrosis factor and anti-interleukin-12/23 antibodies. (C) 2017 Published by Elsevier Masson SAS.
引用
收藏
页码:50 / 59
页数:10
相关论文
共 50 条
  • [21] Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris
    Di Stefani, Alessandro
    Galluzzo, Marco
    Talamonti, Marina
    Chiricozzi, Andrea
    Costanzo, Antonio
    Chimenti, Sergio
    JOURNAL OF DERMATOLOGICAL CASE REPORTS, 2013, 7 (01): : 5 - 9
  • [22] Adalimumab for the Treatment of Pityriasis Rubra Pilaris: A Case Report
    Wassef, Cindy
    Lombardi, Adriana
    Rao, Babar K.
    CUTIS, 2012, 90 (05): : 244 - 247
  • [23] Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris
    Nishimura, Mai
    Kondo, Makoto
    Habe, Koji
    Hayashi, Akinobu
    Yamanaka, Keiichi
    CLINICAL CASE REPORTS, 2022, 10 (10):
  • [24] Pityriasis rubra pilaris: An unusual cutaneous complication of AIDS
    Bonomo, RA
    Korman, N
    NagashimaWhalen, L
    Briggs, J
    Graham, R
    Salata, RA
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 314 (02): : 118 - 121
  • [25] Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin
    Katharina, Medek
    Sylvia, Selhofer
    Matthias, Buchner
    Ulrich, Mrowietz
    Martin, Laimer
    PEDIATRIC DERMATOLOGY, 2022, 39 (04) : 659 - 661
  • [26] Ustekinumab as an Alternative Treatment Option for Chronic Pityriasis Rubra Pilaris
    Chowdhary, Mudit
    Davila, Ulysses
    Cohen, David J.
    CASE REPORTS IN DERMATOLOGY, 2015, 7 (01): : 46 - 50
  • [27] Delayed Presentation of Pityriasis Rubra Pilaris in a Patient on Treatment With Ponatinib
    Yaldo, Marissa M.
    Olds, Hailey
    Hengy, Meredith
    Moossavi, Meena
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [28] Pityriasis rubra pilaris developing after COVID-19
    Kus, Mine Mujde
    Ozturk, Perihan
    Nazik, Hulya
    Mulayim, Mehmet Kamil
    Bulut, Tutku
    Akguc, Esra Rabia
    Kocarslan, Sezen
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2022, 56 (01): : 42 - 45
  • [29] Successful use of etanercept in type I pityriasis rubra pilaris
    Seckin, D.
    Tula, E.
    Ergun, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) : 642 - 644
  • [30] Secukinumab Emerges as a Rapidly Effective Therapy for Pityriasis Rubra Pilaris
    Bonomo, Lauren
    Levitt, Jacob O.
    CUTIS, 2018, 101 (05): : 367 - 369